Current Concepts in the Management of Duchenne Muscular Dystrophy

Springer Science and Business Media LLC - Tập 1 - Trang 65-71 - 2013
Robert J. Rinaldi1, Matthew P. Mayer1, Michael R. Dichiaro2
1Section of Pediatric Rehabilitation Medicine, The Children’s Mercy Hospitals and Clinics, Kansas City, USA
2Department of Pediatric Rehabilitation Medicine, Children’s Hospital Colorado, Aurora, USA

Tóm tắt

The management of Duchenne muscular dystrophy (DMD) has seen dramatic change over the past two decades. Improvements in clinical monitoring of disease progression, management of cardiac and pulmonary complications, and nutritional intervention have all led to decreases in co-morbidity commonly associated with DMD, and, as a consequence, quality of life and life expectancy of individuals with DMD have both continued to improve. This review will update the reader on current trends and recent advances in the diagnosis, management, and treatment of DMD, with a focus on reviewing pertinent current literature.

Tài liệu tham khảo

Gaeta M, Messina S, Mileto A, et al. Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Preliminary experience. Skeletal Radiol. 2012;41(8):955–61.

Finanger EL, Russman B, Forbes SC, et al. Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am. 2012;23(1):1–10.

Otto RK, Ferguson MR, Friedman SD. Cardiac MRI in muscular dystrophy: an overview and future directions. Phys Med Rehabil Clin N Am. 2012;23(1):123–32.

Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging. 2007;25(2):433–40.

Costa AF, Di Primio GA, Schweitzer ME. Magnetic resonance imaging of muscle disease: a pattern-based approach. Muscle Nerve. 2012;46(4):465–81.

• Fischmann A, Hafner P, Gloor M, et al. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol. 2012. doi:10.1007/s00415-012-6733-x This study tests MRI as an objective measure to anticipate functional decline and loss of ambulation. Predictive tools such as this provide important information for patients, families and clinical trials.

Vuillerot C, Girardot F, Payan C, et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Dev Med Child Neurol. 2010;52(1):60–5.

Arpan I, Forbes SC, Lott DJ, et al. T(2) mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy. NMR Biomed. 2012. doi:10.1002/nbm2851

Torriani M, Townsend E, Thomas BJ, et al. Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study. Skeletal Radiol. 2012;41(4):437–45.

Weber MA, Nagel AM, Wolf MB, et al. Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration. J Neurol. 2012;259(11):2385–92.

Lehmann-Horn F, Weber MA, Nagel AM, et al. Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone. Acta Myol. 2012;31(1):31–9.

Karamitsos TD, Neubauer S. Cardiovascular magnetic resonance: a powerful diagnostic and prognostic tool in modern cardiology. Prog Cardiovasc Dis. 2011;54(3):179–80.

Finsterer J. Presence or absence of cardiac disease in Duchenne muscular dystrophy. Cardiology. 2012;121(3):184–5.

Spurney CF. Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve. 2011;44(1):8–19.

•• Davidson ZE, Truby H. A review of nutrition in Duchenne muscular dystrophy. J Hum Nutr Diet. 2009, 22(5):383–93. This study provides a broad, evidence based overview of multiple nutritional considerations in children with DMD. It can be utilized by the provider to create general nutritional management guidelines in their practice.

Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. 2011;16(2):CD004760.

Mok E, Letellier G, Cuisset JM, et al. Lack of functional benefit with glutamine versus placebo in duchenne muscular dystrophy: a randomized crossover trial. PLoS One. 2009;4(5):e5448.

Mok E, Eleouet-Da Violante C, Daubrosse C, et al. Oral glutamine and amino acid supplementation inhibit whole body protein degradation in children with Duchenne muscular dystrophy. Am J Clin Nutr. 2006;83:823–8.

Hankard RG, Hammond D, Haymond MW. Oral gluatamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res. 1998;43:222–6.

Bertorini TE. Neuromuscular disorders: treatment and management. Philadelphia: Suanders Elsevier; 2011.

Martigne L, Seguy D, Pellegrini N, et al. Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr. 2010;29:60–4.

Mizuno T, Komaki H, Sasaki M, et al. Efficacy and tolerance of gastrostomy feeding in Japanese muscular dystrophy patients. Brain Dev. 2012;34:756–62.

Diamanti A, Panetta F, Tentolini A. Efficacy and safety of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr. 2011;30:263.

Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218–26.

Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. 2004;170:456–65.

Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long term effect. Am J Phys Med Rehabil. 2005;84:843–50.

Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001;138:45–50.

Daftary AS, Crisanti M, Kalra M, et al. Effect of longterm steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics. 2007;119:e320.

Buyse GM, Van der Mieren G, Erb M, et al. Long-term blinded placebo controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J. 2009;30:116–24.

Buyse GM, Goemans N, van den Hauewe M, Meier T. Effects of glucocorticoids and idebenone on respiratory function in patients with Duchenne muscular dystrophy. Pediatr Pulmonol. 2012. doi:10.1002/ppul.22688

Kwon SW, Kang S, Kim J, et al. Outcomes of cardiac involvement in patients with late-stage Duchenne muscular dystrophy under management in the pulmonary rehabilitation center of a tertiary referral hospital. Cardiology. 2012;121:186–93.

Markham LW, Kinnett K, Wong BL, et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008;18:365–70.

Ogata H, Ishikawa Y, Minami R, et al. Beneficial effects of beta-blockers and angiotensin converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol. 2009;53:72–8.

Kajimoto H, Ishigaki K, Okumura K. Beta blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J. 2006;70:991–4.

Viollet L, Thrush PT, Flanigan KM, et al. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol. 2012;110:98–102.

Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.

•• Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012; 45(6):796–802. There has been significant discussion about the most appropriate timing for initiating the use of corticosteroid treatment, with current recommendations to discuss initiation when motor gains are often reaching a plateau between ages 4-6. In this study of boys with DMD, 4 of the 5 who began treatment with corticosteroids between 2-4 years of age were ambulatory at ages 17.0-18.5 years, which argues for the benefit of early initiation of corticosteroid treatment, and for the importance of long term studies to investigate the timing of initiation.

Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2012;8:918–28.

Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, Sewry C, et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther. 2012;20:462–7.

Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol. 2012;228:77–87.

Gordon BS, Delgado Díaz DC, Kostek MC. Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy. Clin Nutr. 2013;32(1):104–111. doi: 10.1016/j.clnu.2012.06.003

Nabukera SK, Romitti PA, Campbell KA, Meaney FJ, Caspers KM, Mathews KD, Hockett Sherlock SM, Puzhankara S, Cunniff C, Druschel CM, Pandya S, Matthews DJ, Ciafaloni E. Use of complementary and alternative medicine by males with Duchenne or Becker muscular dystrophy. J Child Neurol. 2012;27:734.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 1

65-71

Thông tin tác giả